Humana Inc. (NYSE:HUM) saw its share price drop to a 52-week low of $212.33, reflecting a steep 42.3% decline over the past ...

The upcoming report from Humana (HUM) is expected to reveal quarterly earnings of $6.32 per share, indicating a decline of 9.2% compared to the year-ago period. Analysts forecast revenues of $31.78 ...

Humana’s worsening fortunes have been a bellwether for the industry, as it has struggled with rising medical costs and ...

Humana faces real challenges like falling Medicare star ratings, shrinking margins, and tough competition. Click here to read ...

Analysts have recently evaluated Humana and provided 12-month price targets. The average target is $280.75, accompanied by a ...

The healthcare sector, including managed-care firms and drug powerhouses, is vastly underperforming the S&P 500 index. Here ...

Humana could face $1 billion to $3 billion in losses next year, with the star ratings drop in its Medicare Advantage program.

It’s a significant loss for the insurer, which sued the government late last year after its star ratings plummeted for 2025.

Revenue Growth: Over the 3M period, Humana showcased positive performance, achieving a revenue growth rate of 10.4% as of 31 December, 2024.

This stock's P/B looks attractive against its industry's average P/B of 2.20. Within the past 52 weeks, HUM's P/B has been as high as 2.91 and as low as 1.52, with a median of 1.93.

This was the stock's fourth consecutive day of losses.